ReST Therapeutics wins FDA IND acceptance for RST-101 as early PTSD treatment strategy enters human testing
ReST Therapeutics’ RST-101 enters human testing for early PTSD. Find out why this IND acceptance could reshape trauma care.
Pharma & Biotech